6-methyl-naphthalene-1,7-diol | 103988-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-methyl-naphthalene-1,7-diol
• 英文别名: 6-Methyl-naphthalin-1,7-diol；6-Methylnaphthalene-1,7-diol
• CAS: 103988-01-8
• 化学式: C₁₁H₁₀O₂
• 分子量: 174.199
• InChiKey: VDXVOKBOYKSSIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  7-甲氧基-6-甲基-3,4-二氢萘-1(2H)-酮 在 氢溴酸 、 sulfur 、 溶剂黄146 作用下， 生成 6-methyl-naphthalene-1,7-diol
  参考文献：
  名称：

  The Metalation of 1,7-Dimethoxynaphthalene¹

  摘要：

  DOI：

  10.1021/ja01526a065

文献信息

• [EN] ELECTROACTIVE COMPOUNDS<br/>[FR] COMPOSÉS ÉLECTROACTIFS
  申请人：DU PONT

  公开号：WO2017210072A1

  公开（公告）日：2017-12-07

  There is provided a compound having Formula (I): (I). In the formula: NpHet is a naphthalene core having at least one fused 5-membered heteroaromatic ring, where the heteroaromatic ring has one heteroatom which is O, S, Se, or Te; Ar1-Ar6 are the same or different and are a hydrocarbon aryl group, a heteroaryl group, or a deuterated analog thereof; a and b are the same or different and are 0 or 1; m and n are the same or different and are 0 or 1; with the proviso that a, b, m, and n are not all 0.

  提供一种具有化学式(I)的化合物：(I)。在该式中：NpHet是至少具有一个融合的5元杂芳环的萘核，其中杂芳环具有一个杂原子，该杂原子是O、S、Se或Te；Ar1-Ar6相同或不同，是一个碳氢芳基团、一个杂芳基团或其氘代物；a和b相同或不同，为0或1；m和n相同或不同，为0或1；但要求a、b、m和n不全为0。
• [EN] N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-CYCLYL-3-(CYCLYLCARBONYLAMINOMÉTHYL)BENZAMIDE EN TANT QU'INHIBITEURS DE LA RHO KINASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012006203A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of formula (I) : and pharmaceutically acceptable salts thereof, wherein R1and R2 are various ring systems. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase mediated diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及化合物的公式（I）及其药学上可接受的盐，其中R1和R2是不同的环系统。该发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗Rho激酶介导的疾病和障碍的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• RHO KINASE INHIBITORS
  申请人：Cook Brian Nicholas

  公开号：US20120165322A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物和其药学上可接受的盐，其中R1和R2的定义如本文所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2590950B1

  公开（公告）日：2014-10-15
• ANTI-MICROBIAL AGENTS AND USES THEREOF
  申请人：Tan Derek Shieh

  公开号：US20090170805A1

  公开（公告）日：2009-07-02

  Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis , rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.